Horizon Pharma Inc. (HZNP: Quote) said Thursday the U.S. Food and Drug Administration has approved RAYOS delayed-release tablets to treat a broad range of diseases.
Indications for RAYOS (prednisone) include rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).
"We are extremely pleased the FDA has approved RAYOS for a broad range of indications, including RA and polymyalgia rheumatica," said Timothy Walbert, chairman, president and chief executive officer, Horizon Pharma.
Walbert further said, "Our initial focus will be on the launch of RAYOS in rheumatologic diseases such as RA and polymyalgia rheumatica in the fourth quarter of this year. Based on the extent of the approved indications, we will be developing a broader commercial strategy to expand the opportunity for RAYOS in key IL-6 mediated diseases, including asthma and COPD."
The FDA approval was supported by data bridging the pharmacokinetics of RAYOS to immediate-release prednisone and data from the Circadian Administration of Prednisone in RA (CAPRA-1 and 2) trials.
The CAPRA-2 trial demonstrated that people with moderate to severe RA treated with RAYOS experienced a statistically significant improvement in ACR20 response criteria compared to placebo. The CAPRA-1 trial supported the overall safety of RAYOS.
 | | To receive FREE breaking news email alerts for Horizon Pharma Inc and others in your portfolio |
|
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com